Edward Tenthoff
Stock Analyst at Piper Sandler
(3.21)
# 1,120
Out of 5,105 analysts
187
Total ratings
45%
Success rate
2.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $26.02 | +72.94% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $89.68 | +39.38% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $13.00 | +76.92% | 6 | Dec 8, 2025 | |
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $29.46 | +113.85% | 13 | Nov 21, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $45 → $70 | $70.09 | -0.13% | 12 | Nov 19, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $2.06 | +191.26% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $397.55 | +23.00% | 15 | Oct 31, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $6.95 | +72.66% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $6.49 | +84.90% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $11.31 | +32.68% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $56.68 | +85.25% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $9.83 | +103.46% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.41 | +396.45% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $12.58 | +11.29% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.56 | +258.62% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $19.27 | +149.09% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $18.07 | +32.82% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $22.32 | +249.46% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $16.52 | +81.60% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $3.11 | +1,990.03% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.09 | +1,734.86% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.38 | +117.39% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.49 | +515.89% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $16.31 | -1.90% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.15 | +421.74% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.41 | +107.47% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $36.80 | +573.91% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.91 | +2,201.79% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $16.94 | +962.57% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.86 | +160.99% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.45 | +396.64% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.13 | +57,628,218.58% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $877.94 | -59.68% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.11 | +12,062.16% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $452.04 | -28.55% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $40.88 | -11.94% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.47 | +1,600.68% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.79 | +18,887.34% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $2.46 | +560,875.61% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $741.29 | - | 11 | Feb 13, 2017 |
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $26.02
Upside: +72.94%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $89.68
Upside: +39.38%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $13.00
Upside: +76.92%
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $29.46
Upside: +113.85%
Arrowhead Pharmaceuticals
Nov 19, 2025
Maintains: Overweight
Price Target: $45 → $70
Current: $70.09
Upside: -0.13%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $2.06
Upside: +191.26%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $397.55
Upside: +23.00%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $6.95
Upside: +72.66%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $6.49
Upside: +84.90%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $11.31
Upside: +32.68%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $56.68
Upside: +85.25%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $9.83
Upside: +103.46%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.41
Upside: +396.45%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $12.58
Upside: +11.29%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.56
Upside: +258.62%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $19.27
Upside: +149.09%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $18.07
Upside: +32.82%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $22.32
Upside: +249.46%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $16.52
Upside: +81.60%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $3.11
Upside: +1,990.03%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.09
Upside: +1,734.86%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.38
Upside: +117.39%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.49
Upside: +515.89%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $16.31
Upside: -1.90%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.15
Upside: +421.74%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $2.41
Upside: +107.47%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $36.80
Upside: +573.91%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.91
Upside: +2,201.79%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $16.94
Upside: +962.57%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.86
Upside: +160.99%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.45
Upside: +396.64%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.13
Upside: +57,628,218.58%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $877.94
Upside: -59.68%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.11
Upside: +12,062.16%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $452.04
Upside: -28.55%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $40.88
Upside: -11.94%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.47
Upside: +1,600.68%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.79
Upside: +18,887.34%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $2.46
Upside: +560,875.61%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $741.29
Upside: -